| Is curcumin bioavailability a problem in humans: lessons from clinical trials |
25 |
| The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments |
16 |
| Chemical activation of estrogen and aryl hydrocarbon receptor signaling pathways and their interaction in toxicology and metabolism |
16 |
| Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies |
16 |
| Side effects associated with current and prospective antimigraine pharmacotherapies |
16 |
| The protective role of melatonin in chemotherapy-induced nephrotoxicity: a systematic review of non-clinical studies |
15 |
| Drug metabolism and metabolite safety assessment in drug discovery and development |
15 |
| Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine |
14 |
| Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters |
13 |
| Novel beta-lactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens |
12 |
| A current structural perspective on PXR and CAR in drug metabolism |
11 |
| Current knowledge of microRNA-mediated regulation of drug metabolism in humans |
11 |
| An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus |
10 |
| A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide |
10 |
| The potential effects of Ocimum basilicum on health: a review of pharmacological and toxicological studies |
10 |
| Metabolism of the failing heart and the impact of SGLT2 inhibitors |
10 |
| Current understanding on pharmacokinetics, clinical efficacy and safety o progestins for treating pain associated to endometriosis |
10 |
| Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions |
9 |
| Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors |
9 |
| Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies |
9 |
| Pharmacogenetics of treatments for pancreatic cancer |
9 |
| Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs |
9 |
| The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs |
9 |
| Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids |
9 |
| Pharmacogenetics of alcohol use disorder treatments: an update |
8 |
| Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis |
8 |
| Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? |
8 |
| Piperine-mediated drug interactions and formulation strategy for piperine: recent advances and future perspectives |
8 |
| Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment |
8 |
| Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment |
8 |
| Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles |
7 |
| What The Cancer Genome Atlas database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs |
7 |
| Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer |
7 |
| Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment |
7 |
| Pharmacokinetics of tazarotene and acitretin in psoriasis |
7 |
| Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer |
7 |
| Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients |
7 |
| Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors |
7 |
| Pharmacokinetics and pharmacodynamics of new acute treatments for migraine |
7 |
| Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1 |
7 |
| Venetoclax in the treatment of chronic lymphocytic leukemia |
7 |
| Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation |
7 |
| Applicability of tumor spheroids for in vitro chemosensitivity assays |
6 |
| Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone |
6 |
| Pharmacokinetics and drug metabolism of antibiotics in the elderly |
6 |
| Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature |
6 |
| ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors |
6 |
| Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle |
6 |
| SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids |
6 |
| Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method |
6 |
